DONALDSON COMPANY, INC. Donaldson Company, Inc. announces that the Gene Therapy Program at the University of Pennsylvania (GTP) is expanding its evaluation agreement aimed at determining the scalability of GTP?s gene therapy product manufacturing using Univercells Technologies? bioreactors. GTP is an academic program focused on genetic medicines led by James M. Wilson, MD, PhD, the Rose H. Weiss Professor and Director of the Orphan Disease Center and a professor of Medicine and Pediatrics at the Perelman School of Medicine.
GTP, renowned for its pioneering work in gene therapy, seeks to make gene therapies for rare diseases accessible worldwide. This agreement covers GTP?s evaluation of the commercial- series scale-X? nitro 600 m2 bioreactor, with the goal of substantially increasing production per batch and potentially reducing cost of goods sold (COGS). This important work between GTP and Univercells Technologies underscores the importance of industry-academic partnerships in advancing the field of gene therapy and accelerating the development and commercialization of life-changing treatments for patients worldwide.
Univercells Technologies developed the scale-X bioreactor with the support of the Bill and Melinda Gates Foundation?s Global Grand Challenge initiative. Originally designed to lower the cost of viral vaccine production for critical public health vaccines, the scale-X bioreactor is now being applied to enable viral vector accessibility for gene therapies.
